Circulating tumor cells in breast cancer

Journal of Carcinogenesis

Volumn 13, Issue 1, 2014, Pages 8-

  Pukazhendhi, Geetha ^a   Glück, Stefan ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

Cellsearch; circulating tumor cells; epithelial cell adhesion molecule; metastatic breast cancer; molecular profiling of circulating tumor cells

Indexed keywords

BETA CATENIN; CD24 ANTIGEN; CYTOKERATIN 19; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; ESTROGEN RECEPTOR; FIBRONECTIN; HERMES ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; MICRORNA; MUCIN 1; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRASTUZUMAB; UVOMORULIN; VIMENTIN; WNT PROTEIN;

ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STEM CELL; CANCER SURVIVAL; CANCER THERAPY; CELL CYCLE ARREST; CIRCULATING TUMOR CELL; DNA METHYLATION; FOLLOW UP; HETEROZYGOSITY LOSS; HUMAN; IMMUNOSURVEILLANCE; MALIGNANT TRANSFORMATION; METHYLATION; MICROMETASTASIS; NONHUMAN; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PRIMARY TUMOR; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROTEIN EXPRESSION; RECURRENCE RISK; TUMOR MICROENVIRONMENT;

EID: 84906777080     PISSN: 09746773     EISSN: 14773163     Source Type: Journal    
DOI: 10.4103/1477-3163.135578     Document Type: Article

References (81)

1. Johnson RH, Chien FL, Bleyer A. Incidence of breast cancer with distant involvement among women in the United States, 1976 to 2009. JAMA 2013;309:800-5.
2. Klein CA. Parallel progression of primary tumours and metastases. Nat Rev Cancer 2009;9:302-12.
3. Swaby RF, Cristofanilli M. Circulating tumor cells in breast cancer: A tool whose time has come of age. BMC Med 2011;9:43.
4. Balic M, Williams A, Lin H, Datar R, Cote RJ. Circulating tumor cells: From bench to bedside. Annu Rev Med 2012;64:31-44.
5. Mego M, Mani SA, Cristofanilli M. Molecular mechanisms of metastasis in breast cancer - clinical applications. Nat Rev Clin Oncol 2010;7:693-701.
6. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 2013;339:580-4.
7. Bastid J. EMT in carcinoma progression and dissemination: Facts, unanswered questions, and clinical considerations. Cancer Metastasis Rev 2012;31:277-83.
8. Bednarz-Knoll N, Alix-Panabières C, Pantel K. Plasticity of disseminating cancer cells in patients with epithelial malignancies. Cancer Metastasis Rev 2012;31:673-87.
9. Langley RR, Fidler IJ. The seed and soil hypothesis revisited - The role of tumor-stroma interactions in metastasis to different organs. Int J Cancer 2011;128:2527-35.
10. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009;9:239-52.
11. Guise T. Examining the metastatic niche: Targeting the microenvironment. Semin Oncol 2010;37 Suppl 2:S2-14.
12. Joosse SA, Hannemann J, Spötter J, Bauche A, Andreas A, Müller V, et al. Changes in keratin expression during metastatic progression of breast cancer: Impact on the detection of circulating tumor cells. Clin Cancer Res 2012;18:993-1003.
13. Bettelheim R, Penman HG, Thornton-Jones H, Neville AM. Prognostic significance of peritumoral vascular invasion in breast cancer. Br J Cancer 1984;50:771-7.
14. Uhr JW, Pantel K. Controversies in clinical cancer dormancy. Proc Natl Acad Sci U S A 2011;108:12396-400.
15. Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF, et al. Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 2004;10:8152-62.
16. Willis L, Alarcón T, Elia G, Jones JL, Wright NA, Tomlinson IP, et al. Breast cancer dormancy can be maintained by small numbers of micrometastases. Cancer Res 2010;70:4310-7.
17. Patel P, Chen EI. Cancer stem cells, tumor dormancy, and metastasis. Front Endocrinol (Lausanne) 2012;3:125.
18. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704-15.
19. May CD, Sphyris N, Evans KW, Werden SJ, Guo W, Mani SA. Epithelial-mesenchymal transition and cancer stem cells: A dangerously dynamic duo in breast cancer progression. Breast Cancer Res 2011;13:202.
20. Korkaya H, Liu S, Wicha MS. Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J Clin Invest 2011;121:3804-9.
21. Korkaya H, Wicha MS. Breast cancer stem cells: We've got them surrounded. Clin Cancer Res 2013;19:511-3.
22. Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res 2009;11:R46.
23. NABAR BV. A study in isolating circulating cancer cells from blood. J Clin Pathol 1962;15:380-2.
24. Pantel K, Alix-Panabières C, Riethdorf S. Cancer micrometastases. Nat Rev Clin Oncol 2009;6:339-51.
25. Joosse SA, Pantel K. Biologic challenges in the detection of circulating tumor cells. Cancer Res 2013;73:8-11.
26. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781-91.
27. Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, et al. Circulating tumor cells: A novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005;23:1420-30.
28. Balic M, Lin H, Williams A, Datar RH, Cote RJ. Progress in circulating tumor cell capture and analysis: Implications for cancer management. Expert Rev Mol Diagn 2012;12:303-12.
29. Alix-Panabières C, Pantel K. Circulating tumor cells: Liquid biopsy of cancer. Clin Chem 2013;59:110-8.
30. Alix-Panabières C, Vendrell JP, Slijper M, Pellé O, Barbotte E, Mercier G, et al. Full-length cytokeratin-19 is released by human tumor cells: A potential role in metastatic progression of breast cancer. Breast Cancer Res 2009;11:R39.
31. Lianidou ES, Markou A. Circulating tumor cells in breast cancer: Detection systems, molecular characterization, and future challenges. Clin Chem 2011;57:1242-55.
32. Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 2008;8:329-40.
33. Andreopoulou E, Yang LY, Rangel KM, Reuben JM, Hsu L, Krishnamurthy S, et al. Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system. Int J Cancer 2012;130:1590-7.
34. Müller V, Riethdorf S, Rack B, Janni W, Fasching PA, Solomayer E, et al. Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: The DETECT study. Breast Cancer Res 2012;14:R118.
35. Madhavan D, Zucknick M, Wallwiener M, Cuk K, Modugno C, Scharpff M, et al. Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clin Cancer Res 2012;18:5972-82.
36. Lippman M, Osborne CK. Circulating tumor DNA - Ready for prime time? N Engl J Med 2013;368:1249-50.
37. Dawson SJ, Rosenfeld N, Caldas C. Circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013;369:93-4.
38. Alix-Panabières C, Schwarzenbach H, Pantel K. Circulating tumor cells and circulating tumor DNA. Annu Rev Med 2012;63:199-215.
39. Müller V, Stahmann N, Riethdorf S, Rau T, Zabel T, Goetz A, et al. Circulating tumor cells in breast cancer: Correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res 2005;11:3678-85.
40. Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 2006;12:4218-24.
41. Bidard FC, Hajage D, Bachelot T, Delaloge S, Brain E, Campone M, et al. Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: A prospective observational study. Breast Cancer Res 2012;14:R29.
42. Cristofanilli M, Broglio KR, Guarneri V, Jackson S, Fritsche HA, Islam R, et al. Circulating tumor cells in metastatic breast cancer: Biologic staging beyond tumor burden. Clin Breast Cancer 2007;7:471-9.
43. Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, Miller MC, et al. Circulating tumor cells versus imaging - Predicting overall survival in metastatic breast cancer. Clin Cancer Res 2006;12:6403-9.
44. Giordano A, Giuliano M, De Laurentiis M, Arpino G, Jackson S, Handy BC, et al. Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: Lack of prediction in HER2-positive disease treated with targeted therapy. Ann Oncol 2012;23:1144-50.
45. Giuliano M, Giordano A, Jackson S, Hess KR, De Giorgi U, Mego M, et al. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res 2011;13:R67.
46. Brugger W, Bross KJ, Glatt M, Weber F, Mertelsmann R, Kanz L. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 1994;83:636-40.
47. Moss TJ, Ross AA. The risk of tumor cell contamination in peripheral blood stem cell collections. J Hematother 1992;1:225-32.
48. Crump M, Gluck S, Tu D, Stewart D, Levine M, Kirkbride P, et al. Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16. J Clin Oncol 2008;26:37-43.
49. Ross AA, Cooper BW, Lazarus HM, Mackay W, Moss TJ, Ciobanu N, et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993;82:2605-10.
50. Ross AA, Layton TJ, Ostrander AB, Passos-Coelho JL, Davis JM, Huelskamp AM, et al. Comparative analysis of breast cancer contamination in mobilized and nonmobilized hematopoietic grafts. J Hematother 1996;5:549-52.
51. Glück S, Ross AA, Layton TJ, Ostrander AB, Goldstein LC, Porter K, et al. Decrease in tumor cell contamination and progenitor cell yield in leukapheresis products after consecutive cycles of chemotherapy for breast cancer treatment. Biol Blood Marrow Transplant 1997;3:316-23.
52. Cooper BW, Moss TJ, Ross AA, Ybanez J, Lazarus HM. Occult tumor contamination of hematopoietic stem-cell products does not affect clinical outcome of autologous transplantation in patients with metastatic breast cancer. J Clin Oncol 1998;16:3509-17.
53. Syme R, Stewart D, Rodriguez-Galvez M, Luider J, Auer Y, Klassen J, et al. Micrometastases in apheresis products predict shorter progression-free and overall survival in patients with breast cancer undergoing high-dose chemotherapy (HDCT) and autologous blood stem cell transplantation (ABSCT). Bone Marrow Transplant 2003;32:307-11.
54. Müller AM, Kohrt HE, Cha S, Laport G, Klein J, Guardino AE, et al. Long-term outcome of patients with metastatic breast cancer treated with high-dose chemotherapy and transplantation of purified autologous hematopoietic stem cells. Biol Blood Marrow Transplant 2012;18:125-33.
55. Nieto Y, Shpall EJ. High-dose chemotherapy with autologous stem cell transplant for breast cancer: What have we learned 25 years later? Biol Blood Marrow Transplant 2012;18:3-5.
56. Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005;353:793-802.
57. Braun S, Pantel K. Micrometastatic bone marrow involvement: Detection and prognostic significance. Med Oncol 1999;16:154-65.
58. Schindlbeck C, Andergassen U, Hofmann S, Jückstock J, Jeschke U, Sommer H, et al. Comparison of circulating tumor cells (CTC) in peripheral blood and disseminated tumor cells in the bone marrow (DTC-BM) of breast cancer patients. J Cancer Res Clin Oncol 2013;139:1055-62.
59. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer 2004;4:448-56.
60. Redding WH, Coombes RC, Monaghan P, Clink HM, Imrie SF, Dearnaley DP, et al. Detection of micrometastases in patients with primary breast cancer. Lancet 1983;2:1271-4.
61. Lucci A, Hall CS, Lodhi AK, Bhattacharyya A, Anderson AE, Xiao L, et al. Circulating tumour cells in non-metastatic breast cancer: A prospective study. Lancet Oncol 2012;13:688-95.
62. Krishnamurthy S, Cristofanilli M, Singh B, Reuben J, Gao H, Cohen EN, et al. Detection of minimal residual disease in blood and bone marrow in early stage breast cancer. Cancer 2010;116:3330-7.
63. Rack BK, Schindlbeck C, Hofmann S, Schneeweiss A, Rezai M, Beckmann MW, et al. Circulating tumor cells in peripheral blood of primary breast cancer patients. J Clin Oncol 2007;25:No 18-Suppl:10595.
64. Lang JE, Mosalpuria K, Cristofanilli M, Krishnamurthy S, Reuben J, Singh B, et al. HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer. Breast Cancer Res Treat 2009;113:501-7.
65. Ignatiadis M, Xenidis N, Perraki M, Apostolaki S, Politaki E, Kafousi M, et al. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. J Clin Oncol 2007;25:5194-202.
66. Bewick M, Chadderton T, Conlon M, Lafrenie R, Morris D, Stewart D, et al. Expression of C-erbB-2/HER2 in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous blood stem cell support. Bone Marrow Transplant 1999;24:377-84.
67. Wülfing P, Borchard J, Buerger H, Heidl S, Zänker KS, Kiesel L, et al. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin Cancer Res 2006;12:1715-20.
68. Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Perkins S, et al. HER2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A 2004;101:9393-8.
69. Georgoulias V, Bozionelou V, Agelaki S, Perraki M, Apostolaki S, Kallergi G, et al. Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: Results of a randomized phase II study. Ann Oncol 2012;23:1744-50.
70. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
71. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005;23:3676-85.
72. Pachmann K, Camara O, Kroll T, Gajda M, Gellner AK, Wotschadlo J, et al. Efficacy control of therapy using circulating epithelial tumor cells (CETC) as "liquid biopsy": Trastuzumab in HER2/neu-positive breast carcinoma. J Cancer Res Clin Oncol 2011;137:1317-27.
73. Prat A, Baselga J. Dual human epidermal growth factor receptor 2 (HER2) blockade and hormonal therapy for the treatment of primary HER2-positive breast cancer: One more step toward chemotherapy-free therapy. J Clin Oncol 2013;31:1703-6.
74. Glück S, Arteaga CL, Osborne CK. Optimizing chemotherapy-free survival for the ER/HER2-positive metastatic breast cancer patient. Clin Cancer Res 2011;17:5559-61.
75. Nadal R, Fernandez A, Sanchez-Rovira P, Salido M, Rodríguez M, García-Puche JL, et al. Biomarkers characterization of circulating tumour cells in breast cancer patients. Breast Cancer Res 2012;14:R71.
76. Dupont Jensen J, Laenkholm AV, Knoop A, Ewertz M, Bandaru R, Liu W, et al. PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer. Clin Cancer Res 2011;17:667-77.
77. Dong X, Alpaugh KR, Cristofanilli M. Circulating tumor cells (CTCs) in breast cancer: A diagnostic tool for prognosis and molecular analysis. Chin J Cancer Res 2012;24:388-98.
78. Chimonidou M, Strati A, Tzitzira A, Sotiropoulou G, Malamos N, Georgoulias V, et al. DNA methylation of tumor suppressor and metastasis suppressor genes in circulating tumor cells. Clin Chem 2011;57:1169-77.
79. Powell AA, Talasaz AH, Zhang H, Coram MA, Reddy A, Deng G, et al. Single cell profiling of circulating tumor cells: Transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS One 2012;7:e33788.
80. Wang X, Sun Q, Mao F, Shen S, Huang L. CTCs hemodialysis: Can it be a new therapy for breast cancer? Med Hypotheses 2013;80:99-101.
81. Carney WP, Neumann R, Lipton A, Leitzel K, Ali S, Price CP. Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer. Clin Breast Cancer 2004;5:105-16.